Paced And Sensed Electrical Delay in CRT Therapy (PASED CRT)
PASED
1 other identifier
interventional
92
1 country
1
Brief Summary
Cardiac resynchronization therapy (CRT) is a well established clinical therapy for patients with symptomatic left ventricular systolic dysfunction and electrocardiographic QRS duration of 120 ms or greater. Multicenter trials have consistently demonstrated CRT "non responder" rates of 32-43% at 6 months. Subsequent studies have shown that utilizing echocardiographic-guided device reprogramming for optimal atrio-ventricular (A-V) and interventricular (VV) delays at rest have improved clinical response. Recently, an echocardiographically validated automated pacemaker programmer-based intra-cardiac electrogram (IEGM) algorithm has been developed for rapid optimization of sino-ventricular (P-V), A-V and V-V delays at resting heart rates that is partially based on the interventricular conduction time delays. Nevertheless, controversy still persists as to the applicability of both echocardiographic and IEGM derived algorithms at elevated heart rates, as with physical activity, when patients are more likely to experience symptoms related to poor cardiac output. Recent studies have shown clinical benefits of pacing from sites of late intrinsic activation or intra-ventricular conduction delays (IVCD). Some studies have utilized the intrinsic SENSED IVCD method while others used the right ventricle (RV)-PACED IVCD. There have not been any studies to date that compare both methods to determine if one may yield a better clinical outcome with lower non-responder rates. This study predicts that the RV paced IVCD method will provide better clinical outcomes than the longest RV sensed IVCD as determined by the clinical composite score. The study is a prospective double blind study with an additional cross-over group consisting only of non-responders to compare the clinical response in 72 patients receiving CRT therapy. After successful CRT-D implantation and before hospital discharge patients will be randomly assigned in a 1:1 fashion to Group 1 (SENSED) or Group 2 (PACED). The patient will complete a Minnesota Living with Heart Failure questionnaire, compare echocardiographic data and be assessed by a blinded nurse and physician prior to discharge and at each follow up visit to maintain the double blind design. After 3 months of follow-up, non-responders from each group will be crossed-over to the other group and followed for an additional 3 months. Clinical data will be collected at the end of that 3 months and compared looking at changes in symptoms, ejection fraction (EF) and other echocardiographic measurements, New York Heart Assocation Function Class ( NYHA) class, clinical composite scores (CCC), device interrogation data and hospital admissions between the two groups to see if there is a statistical difference.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 7, 2016
CompletedFirst Posted
Study publicly available on registry
June 17, 2016
CompletedStudy Start
First participant enrolled
February 2, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 4, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
February 4, 2019
CompletedSeptember 26, 2019
September 1, 2019
2 years
June 7, 2016
September 24, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Change in six-minute walk distance
Six-minute walk distance (measured in meters)
Baseline, 3 months and 6 months. The six month assessment is optional for non-responders participating in crossover option
Secondary Outcomes (1)
Clinical Composite Score
Baseline, 3 months and 6 months. The six month assessment is optional for non-responders participating in crossover option
Study Arms (2)
Paced
ACTIVE COMPARATORPaced arm in which the left heart lead electrode is selected utilizing the longest time to when patient right ventricle lead is pacing. The result of the pacing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
Sensed
ACTIVE COMPARATORSensed arm is based on the longest time that patient own heart's conduction reaches the left heart lead electrode.The result of the sensing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
Interventions
Eligibility Criteria
You may qualify if:
- Ejection Fraction less than or equal to 35%
- American College of Cardiology (ACC)/American Heart Association (AHA) indicated patients with surface ECG QRS duration greater than or equal to 120ms
You may not qualify if:
- Previously placed left ventricular (LV) lead receiving CRT therapy for greater than 3 months
- Pregnant or planning to become pregnant
- Classification of status 1 for cardiac transplant patients for next 9 months,
- Participating in another clinical investigation with an active treatment arm
- Life expectancy of less than nine months
- Age less than 18 years
- Inability to successfully implant LV lead
- Unable to provide written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Deborah Heart and Lung Centerlead
- Abbott Medical Devicescollaborator
Study Sites (1)
Deborah Heart and Lung Center
Browns Mills, New Jersey, 08015, United States
Related Publications (1)
Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001 Jun;7(2):176-82. doi: 10.1054/jcaf.2001.25652.
PMID: 11420770RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Raffaele Corbisiero, MD
Deborah Heart and Lung Center
- PRINCIPAL INVESTIGATOR
Pedram Kazemian, MD
Deborah Heart and Lung Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 7, 2016
First Posted
June 17, 2016
Study Start
February 2, 2017
Primary Completion
February 4, 2019
Study Completion
February 4, 2019
Last Updated
September 26, 2019
Record last verified: 2019-09
Data Sharing
- IPD Sharing
- Will not share